Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Common Equity (2019 - 2025)

Bioadaptives' Common Equity history spans 7 years, with the latest figure at -$2.1 million for Q4 2025.

  • Quarterly results put Common Equity at -$2.1 million for Q4 2025, down 45.5% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (down 45.5% YoY), and the annual figure for FY2025 was -$2.1 million, down 45.5%.
  • Common Equity for Q4 2025 was -$2.1 million at Bioadaptives, down from -$1.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$1.0 million in Q1 2021 to a low of -$2.1 million in Q4 2025.
  • The 5-year median for Common Equity is -$1.5 million (2022), against an average of -$1.5 million.
  • The sharpest move saw Common Equity crashed 57.56% in 2024, then soared 34.07% in 2025.
  • Year by year, Common Equity stood at -$1.1 million in 2021, then plummeted by 32.79% to -$1.5 million in 2022, then fell by 13.44% to -$1.6 million in 2023, then rose by 11.1% to -$1.5 million in 2024, then crashed by 45.5% to -$2.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$2.1 million, -$1.5 million, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.